Characterisation Of The Host Response In A Mouse Model Of Staphylococcus Aureus Keratitis.
Funder
National Health and Medical Research Council
Funding Amount
$248,850.00
Summary
Staphylococcus is the most common cause of bacterial eye infections (microbial keratitis) . This ocular infection is associated with severe pain, redness, discharge and frequently results in the loss of vision or blindness. Predisposing factors for this disease include contact lens wear and immunocompromised individuals such as those with HIV, diabetes or aged populations. S. aureus keratitis is difficult to treat using conventional antibiotics as although bacteria may be eliminated, vision loss ....Staphylococcus is the most common cause of bacterial eye infections (microbial keratitis) . This ocular infection is associated with severe pain, redness, discharge and frequently results in the loss of vision or blindness. Predisposing factors for this disease include contact lens wear and immunocompromised individuals such as those with HIV, diabetes or aged populations. S. aureus keratitis is difficult to treat using conventional antibiotics as although bacteria may be eliminated, vision loss may still result from scarring. S. aureus also causes a wide range of hospital associated infections such as pneumonia, endocarditis, bacteremia, wound infections, osteomyelitis and septic arthritis. In recent times strains of S. aureus have emerged which are multi-drug resistant including methicillin resistant S. aureus (MRSA). These may only be treated with the drug Vancomycin. However, vancomycin resistant S. aureus have been reported in both Japan and the USA. Now, the search for new treatments for this bacterium is of vital importance. This project will utilise the novel S.aureus mouse model for keratitis, which we have developed in our laboratories. Our model will enable us to investigate the host responses to bacterial infection. Existing models in the rabbit do not allow such detailed studies due to the lack of existing molecular probes and antibodies. Insights into potential adjunct therapies will also be gained. This research could lead to the development of novel therapeutic measures aimed at manipulating the host response to reduce scarring and consequent blindness. This information may also be important for the development of prophylactic treatments for those patients at high risk, such as diabetics and immunocompromised individuals of developing this disease.Read moreRead less
Characterisation Of Community Methicillin-resistant Staphylococcus Aureus And Their Control In Remote Communities
Funder
National Health and Medical Research Council
Funding Amount
$300,777.00
Summary
Before the introduction of antibiotics Staphylococcus aureus, the golden staph , was the major cause of infections in hospitals. Although the introduction of antibiotics helped control the organism it has gradually acquired resistance until strains have emerged which can only be treated with vancomycin. Consequently staphs have again emerged as a major hospital pathogen. The emergence of these multiply resistant strains corresponded to them acquiring methicillin resistance and consequently they ....Before the introduction of antibiotics Staphylococcus aureus, the golden staph , was the major cause of infections in hospitals. Although the introduction of antibiotics helped control the organism it has gradually acquired resistance until strains have emerged which can only be treated with vancomycin. Consequently staphs have again emerged as a major hospital pathogen. The emergence of these multiply resistant strains corresponded to them acquiring methicillin resistance and consequently they have come to be known as methicillin-resistant Staphylococcus aureus or MRSA. Soon after the emergence of MRSA the hospitals of Western Australia (WA) developed a policy to prevent introduced MRSA from becoming established in its hospitals. Although this has been successful the policy is now under threat with the emergence of MRSA in remote WA Aboriginal communities. Aboriginals in these communities have a large number of infections which are usually treated empirically. This can result in the selection of antibiotic resistant bacteria if they are present. Consequently, it is planned to regularly screen Aboriginal communities which are known to have a high prevalence of MRSA and recommend antibiotic prescribing which will not select for any resistant staphylococci carried by a person. This is possible because the community MRSA are still susceptible to some anti-staphylococcal drugs. If this program is shown to reduce the prevalence of MRSA in the communities then the program will be extended to other communities. Community MRSA are now being reported from other Australian states and it is planned to study these to see if they are related to the WA strains. The community isolates will be studied to assess their potential to acquire additional antibiotic resistances. As some strains are known to be more of a threat to hospitals than others methods will be investigated to develop rapid methods for detecting them.Read moreRead less
Understanding Virulence Of Invasive Staphylococcus Aureus
Funder
National Health and Medical Research Council
Funding Amount
$772,711.00
Summary
Staph aureus (Golden staph) is a major cause of disease in humans. In this project we will use state-of-the-art molecular biology and genomics to fully understand the mechanisms of virulence in this pathogen. This information will inform future approaches to development of therapeutics, as well as the use of genomics in clinical microbiology and disease management.
Applying Pharmacometrics To Develop Novel Treatment Strategies For Staphylococcus Aureus Infections In Children
Funder
National Health and Medical Research Council
Funding Amount
$368,562.00
Summary
My research will determine the best way to give antibiotics to treat Staphylococcus aureus, one of the most common causes of infection in children. This includes finding out if we can provide highly effective treatment with antibiotics given by mouth instead of through a drip, and with fewer doses each day, so we can treat kids at home instead of in hospital. I will also explore new ways to use common antibiotics to treat antibiotic-resistant infections.
CAMERA: Combination Antibiotic Treatment For Methicillin Resistant Staphylococcus Aureus Bacteraemia - A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,162,248.00
Summary
MRSA (golden staph) is resistant to the most useful class of antibiotics: beta-lactams. It is more difficult to treat than antibiotic-sensitive strains. Standard treatment for MRSA is vancomycin but it has high failure rates. Although MRSA is resistant to beta-lactams, lab studies show that they enhance vancomycin’s bacterial killing when used together. CAMERA2 is an RCT comparing vancomycin alone to combination therapy (vancomycin plus flucloxacillin) for adults with MRSA blood stream infection
Invasive Staphylococcus Aureus Disease In Children; Epidemiology, Treatment And Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$124,676.00
Summary
This project will involve a systematic review of randomised controlled trials (RCT) on the treatment Staphylococcus aureus bacteraemia (SAB) as well as a local WA retrospective review to quantify disease burden, trends and outcome. A prospective 2-year multicentre Australian review will then identify variables that can predict complicated and uncomplicated SAB. This information will then be used to design a RCT protocol on risk-stratified treatment approaches for SAB in paediatrics.
Genomics Dissection And Prevention Of Bacterial Transmission Events
Funder
National Health and Medical Research Council
Funding Amount
$891,290.00
Summary
This project aims at improving public health capacity to limit the spread of infectious diseases in hospital and community settings. The multi-disciplinary team of investigators will link epidemiological data with the finest resolution data from bacterial genomes in order to pinpoint events of infection transmission between individuals. Two high-burden pathogens (golden staph and food-borne Salmonella) will be used as exemplars of infectious diseases with different biology and modes of spread.
Understanding The Contribution Of SRNAs To Antibiotic Resistance In Staphylococcus Aureus
Funder
National Health and Medical Research Council
Funding Amount
$587,424.00
Summary
Golden Staph is a major problem in Australian hospitals. This project will use cutting edge technology to investigate how Golden Staph responds to and resists antibiotics used to treat human infections, leading to new strategies for the prevention and treatment of antibiotic resistant bacteria.
Platelet-Activating And Proinflammatory Effects Of Proteins Secreted By Staphylococcus Aureus
Funder
National Health and Medical Research Council
Funding Amount
$515,986.00
Summary
Skin or other Staphylococcus aureus (SA, golden Staph.) infections are common in Aboriginal Australians. We address the question whether atherosclerotic disease is accelerated by this bacterial infection. We will investigate whether a class of newly described toxins secreted by SA activates blood cells and leads to clot formation and potentially heart attack. We will evaluate plasma samples from cardiac patients and Aboriginal Austr. and will develop and test therapeutics in vitro and in mice.
The Inhibition Of Biotin Protein Ligase As A New Source Of Antibiotics
Funder
National Health and Medical Research Council
Funding Amount
$750,167.00
Summary
We have become so accustomed to treating bacterial infections with antibiotics that it is hard to imagine life without them. However, the emergence of drug-resistance is creating a global health care crisis. Recently, there has not been enough attention paid to replacing old antibiotics with new products to combat drug resistance. Our team is addressing this challenge. We have discovered a new class of antibiotic that is unlike any other drug in clinical use.